A tumor is like a stubborn beast that adapts to any poison. The first blast of chemotherapy kills off some cells, but the survivors quickly learn to ignore the drug. Head and neck cancer is especially treacherous: in roughly half of patients the tumor returns after standard treatment with cisplatin. Cellular senescence is when a cell stops dividing but stays alive, like a beast playing dead.
The new treatment plan works in two moves. First, sacituzumab govitecan enters the fray: an antibody with a toxic payload attached. It seeks out cancer cells by the TROP2 protein on their surface and forces them to age. In experiments on head and neck cancer cells, between 35 and 60 percent of the cells became senescent after this treatment. What's more, cells already resistant to cisplatin aged even more readily.
The second move is the senolytic ABT-263. This drug specifically targets senescent cells and kills them. When the scientists first treated the cells with sacituzumab govitecan and then added ABT-263, between 30 and 60 percent of the cells died. In mouse experiments, this two-step regimen significantly slowed tumor growth and improved survival. It used to be unclear why sacituzumab govitecan performs poorly in head and neck cancer. Now it's clear: it doesn't kill the cells, it merely puts them to sleep. Adding the senolytic keeps them from waking up. This approach could help patients whose tumor has returned after standard treatment.
Sacituzumab govitecan is FDA-approved for metastatic triple-negative breast cancer, but in head and neck cancer trials as a single agent it showed only a modest effect. This work explains why: cells enter senescence and temporarily "fall asleep," then return to dividing. Adding a senolytic prevents them from waking up.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.